GLO1 and hepatocellular carcinoma: Currently, high GLO1 expression has been confirmed in various malignant tumors, including gastric cancer, pancreatic cancer, endometrial cancer, hepatocellular carcinoma, and prostate cancer, and is closely associated with tumor invasion, metastasis, and chemotherapy resistance (143, 145–147).